• Early Life Adversity Weakens Visual Fear via Oxytocin Pathwa

  2026-05-04

  This study demonstrates that early life adversity, specifically social deprivation during a critical postnatal window, impairs innate defensive responses to visual threats in mice through oxytocin signaling deficits in the superior colliculus. The findings advance our mechanistic understanding of how early environment sculpts neural circuits for fear, with implications for neuropsychiatric risk and potential therapeutic directions.

• Azathramycin A: Advanced Mechanisms and Research Protocols

  2026-05-04

  Explore the unique mechanism of Azathramycin A, a macrolide antibiotic, in Mycobacterium tuberculosis research. This article delivers protocol insights and comparative perspectives for advanced antibacterial studies.

• DeferoxamineB: Iron Chelation Workflows in Cancer Research

  2026-05-03

  DeferoxamineB excels as a targeted iron chelator and apoptosis inducer, uniquely supporting metabolic intervention and regulated cell death assays in oncology. This article delivers stepwise protocol guidance, troubleshooting insights, and a synthesis of recent research advances to maximize reliability and innovation in applied cancer workflows.

• RNASEH1-AS1 as a Prognostic lncRNA Target in Hepatocellular

  2026-05-02

  This study identifies the long non-coding RNA RNASEH1-AS1 as an oncogenic driver and independent prognostic biomarker in hepatocellular carcinoma (HCC). Integrating bioinformatics and experimental validation, the authors reveal RNASEH1-AS1’s elevated expression, its association with poor outcomes, and its mechanistic interaction with DKC1.

• Selective FOXM1 Inhibition Overcomes Chemoresistance in Canc

  2026-05-02

  A recent study identified STL427944 as a novel, selective FOXM1 inhibitor that induces autophagic degradation of FOXM1 and sensitizes human cancer cells to standard chemotherapies including taxanes like Docetaxel. This work provides mechanistic insight into overcoming chemoresistance through targeted gene network analysis, advancing opportunities for more effective cancer chemotherapy research.

• Gepotidacin (GSK2140944): Optimizing Antibacterial Research

  2026-05-01

  Gepotidacin (GSK2140944) stands out as a first-in-class, dual-targeting bacterial DNA gyrase and topoisomerase IV inhibitor, uniquely addressing fluoroquinolone resistance. This article delivers actionable guidance for experimental design, troubleshooting, and advanced antibacterial research using Gepotidacin, leveraging the latest high-throughput screening and mechanistic insights.

• Bestatin Hydrochloride (Ubenimex): Mechanisms & Research Val

  2026-04-30

  Bestatin hydrochloride (Ubenimex) is a highly characterized inhibitor of aminopeptidase N and B, widely utilized in cancer research for its effects on angiogenesis and tumor cell biology. Its mechanism, benchmarks, and workflow applications are supported by stable peer-reviewed evidence and rigorous product characterization.

• 10058-F4: c-Myc-Max Dimerization Inhibitor in Cancer Researc

  2026-04-30

  10058-F4 is a validated small-molecule c-Myc-Max dimerization inhibitor that disrupts oncogenic transcription and promotes apoptosis in leukemia and prostate cancer models. It enables targeted study of c-Myc-driven signaling and has defined protocol parameters for reliable experimental outcomes.

• EZ Cap™ Firefly Luciferase mRNA (5-moUTP): Stability & Effic

  2026-04-29

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) delivers robust, low-immunogenic protein expression for reporter assays and gene regulation studies. Its Cap 1 structure and 5-moUTP modifications synergistically suppress innate immune activation and enhance mRNA stability, supporting reproducible, high-fidelity results in mRNA delivery and translation efficiency assays.

• Cy5 TSA Fluorescence System Kit: Amplifying Detection in IHC

  2026-04-29

  The Cy5 TSA Fluorescence System Kit supercharges immunohistochemistry, immunocytochemistry, and in situ hybridization workflows with rapid, HRP-catalyzed tyramide deposition and up to 100-fold sensitivity gains. Discover data-driven strategies for robust detection of low-abundance targets, troubleshooting, and protocol refinement that set this system apart for advanced neurobiology and beyond.

• Applied Workflows with FLAG tag Peptide (DYKDDDDK): Protocol

  2026-04-28

  The FLAG tag Peptide (DYKDDDDK) empowers precise, high-yield recombinant protein purification, combining gentle elution with robust detection. This guide delivers actionable protocols, troubleshooting insights, and fresh perspectives by bridging recent structural biology findings and practical lab workflows.

• SLC11A1 Activates TGF-β1 Pathway to Resist Ferroptosis in CR

  2026-04-28

  This study uncovers a mechanistic link between high SLC11A1 expression and resistance to ferroptosis in colorectal cancer, mediated by activation of the TGF-β1 signaling pathway. The findings highlight SLC11A1 as a potential therapeutic target and suggest new avenues for overcoming treatment resistance.

• MG-132: Translational Strategies for Targeting the Ubiquitin

  2026-04-27

  This article explores how MG-132 (Z-LLL-al), a peptide aldehyde proteasome inhibitor, is redefining experimental paradigms in apoptosis assays, cell cycle arrest studies, and cancer research. We bridge current mechanistic understanding—including connections to the YTHDF2/m6A/UBE3C axis and ovarian aging—with actionable guidance for translational researchers. By integrating validated protocol parameters, competitive context, and a forward vision, we position APExBIO’s MG-132 as an indispensable tool for advanced biology.

• Applied Workflows with Murine Recombinant PDGF-BB in Vascula

  2026-04-27

  Murine recombinant PDGF-BB enables precise modulation of cell proliferation and metabolic remodeling in vascular research, with relevance to pulmonary hypertension and beyond. This guide details robust experimental workflows, actionable troubleshooting, and leverages the latest mechanistic insights to maximize reproducibility and interpretive power.

• PP 1: Applied Workflows for Src Family Tyrosine Kinase Inhib

  2026-04-26

  PP 1, a potent Src family tyrosine kinase inhibitor, enables precise dissection of cancer and immune signaling in both cell-based and in vivo models. This guide delivers stepwise workflows, troubleshooting strategies, and reference-driven optimizations for robust pathway interrogation and advanced biomarker studies.

16951 records 1/1131 page Next 12345 下5页 Last page